Richard Bergström Quits EFPIA
The director general leaves his position at the European Federation of Pharmaceutical Industries and Associations (EFPIA) after five years to pursue “a fresh challenge.”
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has announced that its director general, Richard Bergström, is leaving the post.
“I am proud to leave EFPIA at a time when we have developed policies that promote innovation and patient access, such as through the focus on outcomes and on adaptive pathways to speed up the development of new medicines. After 15 fantastic years leading industry associations in Sweden and in Brussels, it is time for me to take on a fresh challenge,” he said.
Bergström succeeded Brian Ager as director general on April 1, 2011. He was previously director general of LIF, the Swedish research-based pharmaceutical industry association. He is a pharmacist by trade who worked for almost 20 years in the pharmaceutical industry, before moving to LIF in 2002.
Previously Bergström was chair of EFPIA’s Trust Committee and Task Force on Health Technology Assessment and a council member of the International Federation of Pharmaceutical Manufacturers Associations (IFPMA). He served on several Swedish government commissions and was vice chairman of the board of the Karolinska Institutet.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
